ATE521356T1 - Kohlehydraten oder 2'-modifizierten oligonukleotiden mit alternierenden internukleoside-bindungen - Google Patents
Kohlehydraten oder 2'-modifizierten oligonukleotiden mit alternierenden internukleoside-bindungenInfo
- Publication number
- ATE521356T1 ATE521356T1 AT99933747T AT99933747T ATE521356T1 AT E521356 T1 ATE521356 T1 AT E521356T1 AT 99933747 T AT99933747 T AT 99933747T AT 99933747 T AT99933747 T AT 99933747T AT E521356 T1 ATE521356 T1 AT E521356T1
- Authority
- AT
- Austria
- Prior art keywords
- bondies
- carbohydrates
- modified oligonucleotides
- internucleoside
- alternate
- Prior art date
Links
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Chemical class Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
- 150000001720 carbohydrates Chemical class 0.000 title 1
- 235000014633 carbohydrates Nutrition 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 108091034117 Oligonucleotide Proteins 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000003278 mimic effect Effects 0.000 abstract 1
- 108020004707 nucleic acids Proteins 0.000 abstract 1
- 150000007523 nucleic acids Chemical class 0.000 abstract 1
- 102000039446 nucleic acids Human genes 0.000 abstract 1
- 125000003835 nucleoside group Chemical group 0.000 abstract 1
- 150000004713 phosphodiesters Chemical class 0.000 abstract 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/334—Modified C
- C12N2310/3341—5-Methylcytosine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/115,025 US6277967B1 (en) | 1998-07-14 | 1998-07-14 | Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages |
| PCT/US1999/015347 WO2000003720A1 (en) | 1998-07-14 | 1999-07-07 | Carbohydrate or 2'-modified oligonucleotides having alternating internucleoside linkages |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE521356T1 true ATE521356T1 (de) | 2011-09-15 |
Family
ID=22358885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT99933747T ATE521356T1 (de) | 1998-07-14 | 1999-07-07 | Kohlehydraten oder 2'-modifizierten oligonukleotiden mit alternierenden internukleoside-bindungen |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US6277967B1 (de) |
| EP (1) | EP1104303B1 (de) |
| AT (1) | ATE521356T1 (de) |
| AU (1) | AU4973899A (de) |
| DK (1) | DK1104303T3 (de) |
| ES (1) | ES2369875T3 (de) |
| WO (1) | WO2000003720A1 (de) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7812149B2 (en) | 1996-06-06 | 2010-10-12 | Isis Pharmaceuticals, Inc. | 2′-Fluoro substituted oligomeric compounds and compositions for use in gene modulations |
| US9096636B2 (en) | 1996-06-06 | 2015-08-04 | Isis Pharmaceuticals, Inc. | Chimeric oligomeric compounds and their use in gene modulation |
| US5898031A (en) | 1996-06-06 | 1999-04-27 | Isis Pharmaceuticals, Inc. | Oligoribonucleotides for cleaving RNA |
| US20040171028A1 (en) * | 1996-06-06 | 2004-09-02 | Baker Brenda F. | Phosphorous-linked oligomeric compounds and their use in gene modulation |
| AU3465599A (en) * | 1998-04-01 | 1999-10-18 | Hybridon, Inc. | Mixed-backbone oligonucleotides containing pops blocks to obtain reduced phosphorothioate content |
| US6277967B1 (en) | 1998-07-14 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages |
| US20030220486A1 (en) * | 1999-04-01 | 2003-11-27 | Wen-Qiang Zhou | Mixed backbone oligonucleotides containing pops blocks to obtain reduced phosphorothioate content |
| DE10019252A1 (de) * | 2000-04-18 | 2001-10-31 | Klaus Karl Degitz | Polydesoxyribonukleotide zur Hemmung der ICAM-1-Genexpression |
| US8278103B2 (en) * | 2002-02-01 | 2012-10-02 | Mcgill University | Oligonucleotides comprising alternating segments and uses thereof |
| AU2003291755A1 (en) | 2002-11-05 | 2004-06-07 | Isis Pharmaceuticals, Inc. | Oligomers comprising modified bases for binding cytosine and uracil or thymine and their use |
| WO2005072057A2 (en) | 2004-01-30 | 2005-08-11 | Quark Biotech, Inc. | Oligoribonucleotides and methods of use thereof for treatment of fibrotic conditions and other diseases |
| US8569474B2 (en) | 2004-03-09 | 2013-10-29 | Isis Pharmaceuticals, Inc. | Double stranded constructs comprising one or more short strands hybridized to a longer strand |
| KR101147147B1 (ko) | 2004-04-01 | 2012-05-25 | 머크 샤프 앤드 돔 코포레이션 | Ｒｎａ 간섭의 오프 타겟 효과 감소를 위한 변형된폴리뉴클레오타이드 |
| US8394947B2 (en) | 2004-06-03 | 2013-03-12 | Isis Pharmaceuticals, Inc. | Positionally modified siRNA constructs |
| US7884086B2 (en) | 2004-09-08 | 2011-02-08 | Isis Pharmaceuticals, Inc. | Conjugates for use in hepatocyte free uptake assays |
| AU2005288522B2 (en) | 2004-09-28 | 2012-06-28 | Quark Pharmaceuticals, Inc. | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
| US20060166234A1 (en) | 2004-11-22 | 2006-07-27 | Barbara Robertson | Apparatus and system having dry control gene silencing compositions |
| US7935811B2 (en) | 2004-11-22 | 2011-05-03 | Dharmacon, Inc. | Apparatus and system having dry gene silencing compositions |
| US7923207B2 (en) | 2004-11-22 | 2011-04-12 | Dharmacon, Inc. | Apparatus and system having dry gene silencing pools |
| AU2007299705B2 (en) | 2006-09-22 | 2012-09-06 | Dharmacon, Inc. | Duplex oligonucleotide complexes and methods for gene silencing by RNA interference |
| EP1935434A1 (de) * | 2006-12-19 | 2008-06-25 | Novosom AG | Konstruktion und Verwendung von transfektionsverstärkenden Elementen |
| WO2009039300A2 (en) * | 2007-09-18 | 2009-03-26 | Intradigm Corporation | Compositions comprising hif-1 alpha sirna and methods of use thereof |
| JP2010538678A (ja) * | 2007-09-18 | 2010-12-16 | イントラドイグム コーポレーション | Ｋ−ｒａｓｓｉＲＮＡ含有組成物及びそれらの使用法 |
| US7845686B2 (en) * | 2007-12-17 | 2010-12-07 | S & B Technical Products, Inc. | Restrained pipe joining system for plastic pipe |
| CA2715289C (en) | 2008-02-11 | 2019-12-24 | Rxi Pharmaceuticals Corporation | Modified rnai polynucleotides and uses thereof |
| US8188060B2 (en) | 2008-02-11 | 2012-05-29 | Dharmacon, Inc. | Duplex oligonucleotides with enhanced functionality in gene regulation |
| CA2717496A1 (en) * | 2008-03-12 | 2009-09-17 | Intradigm Corporation | Compositions comprising notch1 sirna and methods of use thereof |
| US8815818B2 (en) | 2008-07-18 | 2014-08-26 | Rxi Pharmaceuticals Corporation | Phagocytic cell delivery of RNAI |
| EP2342340A1 (de) | 2008-09-22 | 2011-07-13 | Rxi Pharmaceuticals Corporation | Rna-interferenz bei hautindikationen |
| WO2010059226A2 (en) | 2008-11-19 | 2010-05-27 | Rxi Pharmaceuticals Corporation | Inhibition of map4k4 through rnai |
| WO2010078536A1 (en) | 2009-01-05 | 2010-07-08 | Rxi Pharmaceuticals Corporation | Inhibition of pcsk9 through rnai |
| US9745574B2 (en) | 2009-02-04 | 2017-08-29 | Rxi Pharmaceuticals Corporation | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
| NZ714887A (en) | 2009-09-11 | 2019-07-26 | Ionis Pharmaceuticals Inc | Modulation of huntingtin expression |
| US8841429B2 (en) | 2009-11-03 | 2014-09-23 | Vivonics, Inc. | Nucleic acid ligands against infectious prions |
| US8236570B2 (en) | 2009-11-03 | 2012-08-07 | Infoscitex | Methods for identifying nucleic acid ligands |
| CN103200945B (zh) | 2010-03-24 | 2016-07-06 | 雷克西制药公司 | 眼部症候中的rna干扰 |
| RU2615143C2 (ru) | 2010-03-24 | 2017-04-04 | Адвирна | Самодоставляющие PHKi соединения уменьшенного размера |
| EP3560503B1 (de) | 2010-03-24 | 2021-11-17 | Phio Pharmaceuticals Corp. | Rna-interferenz bei dermalen und fibrotischen erkrankungen |
| WO2013089522A1 (ko) | 2011-12-15 | 2013-06-20 | (주)바이오니아 | 신규한 올리고뉴클레오티드 접합체 및 그 용도 |
| JP6060178B2 (ja) * | 2012-01-05 | 2017-01-18 | バイオニア コーポレーションＢｉｏｎｅｅｒ Ｃｏｒｐｏｒａｔｉｏｎ | 高効率のナノ粒子型二本鎖オリゴｒｎａ構造体およびその製造方法 |
| KR20150064065A (ko) | 2012-10-05 | 2015-06-10 | (주)바이오니아 | 엠피레귤린 특이적 이중 나선 올리고 rna, 그러한 이중나선 올리고 rna 를 포함하는 이중나선 올리고 rna 구조체 및 이를 포함하는 호흡기 질환의 예방 또는 치료용 조성물 |
| CN110592082A (zh) | 2013-07-05 | 2019-12-20 | 柏业公司 | 呼吸疾病相关基因特异性siRNA、含有siRNA的双螺旋寡RNA结构及其用途 |
| CN105705639A (zh) | 2013-07-05 | 2016-06-22 | 柏业公司 | 登革病毒相关的基因特异性siRNA、包含该siRNA的双链寡RNA分子、和包含它们的用于抑制登革病毒复制的组合物 |
| BR112016000160B1 (pt) | 2013-07-05 | 2021-06-08 | Bioneer Corporation | estrutura de oligonucleotídeo tipo nanopartícula melhorada tendo alta eficiência e método para a preparação da mesma |
| CN106061488B (zh) | 2013-12-02 | 2021-04-09 | 菲奥医药公司 | 癌症的免疫治疗 |
| EP3128008B1 (de) | 2014-04-04 | 2024-05-29 | Bioneer Corporation | Doppelsträngige-oligo-rna und pharmazeutische zusammensetzung damit zur prävention oder behandlung von fibrose oder atemwegserkrankungen |
| WO2015168108A2 (en) | 2014-04-28 | 2015-11-05 | Rxi Pharmaceuticals Corporation | Methods for treating cancer using nucleic targeting mdm2 or mycn |
| US10900039B2 (en) | 2014-09-05 | 2021-01-26 | Phio Pharmaceuticals Corp. | Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1 |
| JP2018515142A (ja) * | 2015-05-15 | 2018-06-14 | ダーマコン，インコーポレイテッド． | Ｃａｓ９介在遺伝子編集用の合成シングルガイドｒｎａ |
| EP3862005A1 (de) | 2015-07-06 | 2021-08-11 | Phio Pharmaceuticals Corp. | Gegen superoxid-dismutase 1 (sod1) gerichtete nukleinsäuremoleküle |
| US10808247B2 (en) | 2015-07-06 | 2020-10-20 | Phio Pharmaceuticals Corp. | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
| WO2017070151A1 (en) | 2015-10-19 | 2017-04-27 | Rxi Pharmaceuticals Corporation | Reduced size self-delivering nucleic acid compounds targeting long non-coding rna |
| CA3033867A1 (en) | 2016-08-17 | 2018-02-22 | Solstice Biologics, Ltd. | Polynucleotide constructs |
| WO2018051762A1 (ja) * | 2016-09-14 | 2018-03-22 | レナセラピューティクス株式会社 | 副作用を減じたアンチセンス核酸 |
| US12544344B2 (en) | 2017-04-19 | 2026-02-10 | Phio Pharmaceuticals Corp. | Topical delivery of nucleic acid compounds |
| US11597744B2 (en) | 2017-06-30 | 2023-03-07 | Sirius Therapeutics, Inc. | Chiral phosphoramidite auxiliaries and methods of their use |
| KR102746742B1 (ko) | 2018-05-25 | 2024-12-26 | (주)바이오니아 | 엠피레귤린 유전자 특이적 이중가닥 올리고뉴클레오티드 및 이를 포함하는 섬유증 관련 질환 및 호흡기 관련 질환 예방 및 치료용 조성물 |
| KR102473989B1 (ko) | 2018-11-28 | 2022-12-07 | (주)바이오니아 | 안드로젠 수용체 특이적 서열을 포함하는 이중나선 올리고뉴클레오티드 구조체, 및 이를 포함하는 탈모 예방 및 발모용 조성물 |
| WO2020149644A1 (ko) | 2019-01-15 | 2020-07-23 | (주)바이오니아 | Dkk1 유전자를 표적으로 하는 이중나선 올리고뉴클레오티드, 이를 포함하는 구조체 및 이를 포함하는 탈모 예방 또는 발모용 조성물 |
| JPWO2020171149A1 (ja) * | 2019-02-22 | 2021-12-16 | 国立大学法人 東京医科歯科大学 | ヘテロ核酸の最適ｐｓ修飾パターン |
| BR112022007795A2 (pt) * | 2019-11-06 | 2022-07-05 | Alnylam Pharmaceuticals Inc | Administração extra-hepática |
| KR102757180B1 (ko) | 2019-11-22 | 2025-01-21 | (주)바이오니아 | Ctgf 유전자 특이적 이중가닥 올리고뉴클레오티드 및 이를 포함하는 섬유증 관련 질환 및 호흡기 관련 질환 예방 및 치료용 조성물 |
| EP4151236A4 (de) | 2020-05-14 | 2024-06-26 | Bioneer Corporation | Zusammensetzung zur prävention oder behandlung von erkrankungen im zusammenhang mit aphiregulin mit amphiregulinspezifischer doppelsträngiger oligonukleotidstruktur |
| AU2021275643A1 (en) | 2020-05-22 | 2022-12-15 | Bioneer Corporation | Double-stranded oligonucleotide and composition for treating covid-19 containing same |
| EP3922720A1 (de) | 2020-06-09 | 2021-12-15 | Universidad de Murcia | Therapie zur verhinderung unerwünschter kardialer remodellierung nach einem akuten myokardinfarkt |
| KR102272800B1 (ko) | 2020-06-30 | 2021-07-05 | 국방과학연구소 | 코로나바이러스 특이적 이중가닥 올리고뉴클레오티드 및 이를 포함하는 코로나바이러스 감염증-19 예방 및 치료용 조성물 |
| EP4689111A1 (de) | 2023-03-29 | 2026-02-11 | Sir Nagen Therapeutics Incorporated | Auf den androgenrezeptor abzielender dna-rna-heteroduplex |
Family Cites Families (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3687808A (en) | 1969-08-14 | 1972-08-29 | Univ Leland Stanford Junior | Synthetic polynucleotides |
| NZ209840A (en) | 1983-10-17 | 1988-11-29 | Kaji Akira | A method of inhibiting viral propagation by hybridising dna with the viral rna thus blocking its action |
| US4806463A (en) | 1986-05-23 | 1989-02-21 | Worcester Foundation For Experimental Biology | Inhibition of HTLV-III by exogenous oligonucleotides |
| US5194428A (en) | 1986-05-23 | 1993-03-16 | Worcester Foundation For Experimental Biology | Inhibition of influenza virus replication by oligonucleotide phosphorothioates |
| US5264423A (en) | 1987-03-25 | 1993-11-23 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| US5004810A (en) | 1988-09-30 | 1991-04-02 | Schering Corporation | Antiviral oligomers |
| DE69034150T2 (de) * | 1989-10-24 | 2005-08-25 | Isis Pharmaceuticals, Inc., Carlsbad | 2'-Modifizierte Oligonukleotide |
| US5457189A (en) | 1989-12-04 | 1995-10-10 | Isis Pharmaceuticals | Antisense oligonucleotide inhibition of papillomavirus |
| US5620963A (en) | 1991-10-15 | 1997-04-15 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating protein kinase C having phosphorothioate linkages of high chiral purity |
| US5212295A (en) | 1990-01-11 | 1993-05-18 | Isis Pharmaceuticals | Monomers for preparation of oligonucleotides having chiral phosphorus linkages |
| US5591623A (en) | 1990-08-14 | 1997-01-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
| US5670633A (en) | 1990-01-11 | 1997-09-23 | Isis Pharmaceuticals, Inc. | Sugar modified oligonucleotides that detect and modulate gene expression |
| US5587361A (en) | 1991-10-15 | 1996-12-24 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US5514788A (en) | 1993-05-17 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
| US5220007A (en) * | 1990-02-15 | 1993-06-15 | The Worcester Foundation For Experimental Biology | Method of site-specific alteration of RNA and production of encoded polypeptides |
| US5514577A (en) | 1990-02-26 | 1996-05-07 | Isis Pharmaceuticals, Inc. | Oligonucleotide therapies for modulating the effects of herpes viruses |
| US5248670A (en) | 1990-02-26 | 1993-09-28 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides for inhibiting herpesviruses |
| US5166195A (en) | 1990-05-11 | 1992-11-24 | Isis Pharmaceuticals, Inc. | Antisense inhibitors of the human immunodeficiency virus phosphorothioate oligonucleotides |
| US6111094A (en) | 1990-08-14 | 2000-08-29 | Isis Pharmaceuticals Inc. | Enhanced antisense modulation of ICAM-1 |
| HUT69956A (en) | 1990-08-14 | 1995-09-28 | Isis Pharmaceuticals Inc | Methode for inhibition of influenza virus by antiseuse oligonucleotides |
| US5843738A (en) | 1990-08-14 | 1998-12-01 | Isis Pharmaceuticals, Inc. | Oligonucleotide modulation of cell adhesion |
| ES2104717T3 (es) | 1990-08-16 | 1997-10-16 | Isis Pharmaceuticals Inc | Oligonucleotidos para modular los efectos de las infecciones por citomegalovirus. |
| US5442049A (en) | 1992-11-19 | 1995-08-15 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating the effects of cytomegalovirus infections |
| US5691461A (en) | 1990-08-16 | 1997-11-25 | Isis Pharmaceuticals, Inc. | Oligonucleotides inhibiting candida germ tube formation |
| US5242906A (en) | 1991-04-22 | 1993-09-07 | University Of North Carolina At Chapel Hill | Antisense oligonucleotides against Epstein-Barr virus |
| WO1994008003A1 (en) | 1991-06-14 | 1994-04-14 | Isis Pharmaceuticals, Inc. | ANTISENSE OLIGONUCLEOTIDE INHIBITION OF THE ras GENE |
| ATE186072T1 (de) | 1991-06-14 | 1999-11-15 | Isis Pharmaceuticals Inc | Antisense-oligonukleotid-inhibition des ras-gen |
| US5582986A (en) | 1991-06-14 | 1996-12-10 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotide inhibition of the ras gene |
| US5661134A (en) | 1991-10-15 | 1997-08-26 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating Ha-ras or Ki-ras having phosphorothioate linkages of high chiral purity |
| US5599797A (en) | 1991-10-15 | 1997-02-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides having phosphorothioate linkages of high chiral purity |
| US5607923A (en) | 1991-10-15 | 1997-03-04 | Isis Pharmaceuticals, Inc. | Oligonucleotides for modulating cytomegalovirus having phosphorothioate linkages of high chiral purity |
| DE69233046T2 (de) | 1991-10-24 | 2004-03-04 | Isis Pharmaceuticals, Inc., Carlsfeld | Derivatisierte oligonukleotide mit verbessertem aufnahmevermögen |
| EP0635023B1 (de) | 1992-03-05 | 2002-02-06 | Isis Pharmaceuticals, Inc. | Kovalent vernetzte oligonukleotide |
| US5681747A (en) | 1992-03-16 | 1997-10-28 | Isis Pharmaceuticals, Inc. | Nucleic acid sequences encoding protein kinase C and antisense inhibition of expression thereof |
| US5523389A (en) | 1992-09-29 | 1996-06-04 | Isis Pharmaceuticals, Inc. | Inhibitors of human immunodeficiency virus |
| US5985558A (en) | 1997-04-14 | 1999-11-16 | Isis Pharmaceuticals Inc. | Antisense oligonucleotide compositions and methods for the inibition of c-Jun and c-Fos |
| IL111660A (en) | 1993-11-16 | 2005-05-17 | Genta Inc | Oligonucleoside compounds for effecting rnaseh-mediated cleavage of a target ribonucleic acid sequence and a pharmaceutical composition containing them |
| KR960000183Y1 (ko) | 1993-11-17 | 1996-01-05 | 정헌운 | 자동차용 유아보호 의자 |
| US6166197A (en) | 1995-03-06 | 2000-12-26 | Isis Pharmaceuticals, Inc. | Oligomeric compounds having pyrimidine nucleotide (S) with 2'and 5 substitutions |
| CA2256765A1 (en) * | 1996-06-06 | 1997-12-11 | Novartis Ag | 2'-substituted nucleosides and oligonucleotide derivatives |
| US6172209B1 (en) | 1997-02-14 | 2001-01-09 | Isis Pharmaceuticals Inc. | Aminooxy-modified oligonucleotides and methods for making same |
| US6127533A (en) | 1997-02-14 | 2000-10-03 | Isis Pharmaceuticals, Inc. | 2'-O-aminooxy-modified oligonucleotides |
| US5877309A (en) | 1997-08-13 | 1999-03-02 | Isis Pharmaceuticals, Inc. | Antisense oligonucleotides against JNK |
| US5955443A (en) | 1998-03-19 | 1999-09-21 | Isis Pharmaceuticals Inc. | Antisense modulation of PECAM-1 |
| US6277967B1 (en) | 1998-07-14 | 2001-08-21 | Isis Pharmaceuticals, Inc. | Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages |
| US6271358B1 (en) | 1998-07-27 | 2001-08-07 | Isis Pharmaceuticals, Inc. | RNA targeted 2′-modified oligonucleotides that are conformationally preorganized |
-
1998
- 1998-07-14 US US09/115,025 patent/US6277967B1/en not_active Expired - Lifetime
-
1999
- 1999-07-07 ES ES99933747T patent/ES2369875T3/es not_active Expired - Lifetime
- 1999-07-07 EP EP99933747A patent/EP1104303B1/de not_active Expired - Lifetime
- 1999-07-07 AU AU49738/99A patent/AU4973899A/en not_active Abandoned
- 1999-07-07 WO PCT/US1999/015347 patent/WO2000003720A1/en not_active Ceased
- 1999-07-07 US US09/349,007 patent/US6326358B1/en not_active Expired - Lifetime
- 1999-07-07 DK DK99933747.0T patent/DK1104303T3/da active
- 1999-07-07 AT AT99933747T patent/ATE521356T1/de not_active IP Right Cessation
-
2001
- 2001-09-27 US US09/965,551 patent/US7056896B2/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| US7056896B2 (en) | 2006-06-06 |
| EP1104303A4 (de) | 2002-03-27 |
| US6326358B1 (en) | 2001-12-04 |
| DK1104303T3 (da) | 2011-12-19 |
| WO2000003720A1 (en) | 2000-01-27 |
| AU4973899A (en) | 2000-02-07 |
| EP1104303B1 (de) | 2011-08-24 |
| EP1104303A1 (de) | 2001-06-06 |
| ES2369875T3 (es) | 2011-12-07 |
| US20020165181A1 (en) | 2002-11-07 |
| US6277967B1 (en) | 2001-08-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE521356T1 (de) | Kohlehydraten oder 2'-modifizierten oligonukleotiden mit alternierenden internukleoside-bindungen | |
| ATE316094T1 (de) | Oligonukleotide mit für bindungstaschen spezifischen chiralen phosphorothioat- internukleosidbindungen | |
| DE69403642D1 (de) | 7-deazapurin modifizierte oligonukleotide | |
| DE69620906D1 (de) | Antisense-oligonukleotidmodulation der raf-genexpression | |
| ATE280772T1 (de) | Antisense oligonukleotidmodulation der raf genexpression | |
| ATE139255T1 (de) | Oligonukleotidanaloga mit neuartigen bindungen | |
| DE69633679D1 (de) | Substituierte aryl-oder heteroarylamide mit retinoid-ähnlicher biologischer aktivität | |
| NZ331358A (en) | Methoxyethoxy oligonucleotides for modulation of protein kinase c expression | |
| CY1110633T1 (el) | Τροποποιηση αντιθετης φορας της εκφρασης σουρβιβινης | |
| WO1999051731A3 (en) | Maize histone deacetylases and their use | |
| EP1009860A4 (de) | Antisense oligonukleotid zur inhibierung von ras | |
| ATE275956T1 (de) | Veränderung der dns methyltransferase durch kombinationstherapie | |
| DK0819135T3 (da) | Kulhydratmodificerede cytostatika | |
| EP1123414A4 (de) | Antisense modulation der expression von integrin alpha 4 | |
| EP1131332A4 (de) | Antisense-modulation der inhibitor-kappa b kinase-beta expression | |
| EP1131107A4 (de) | Antisense-modulation der expression von inhibitor-kappa-b-kinase-alpha | |
| IL131014A0 (en) | Methods for cultivating cells and propagating viruses | |
| DE69023430D1 (de) | Enzymelektrode. | |
| ZA200101737B (en) | Nucleic acid molecules which code for enzymes with fructosyltransferase activity and use thereof. | |
| EP1163373A4 (de) | Antisense-modulation des zellulären hemmstoffs der apoptosis-expression | |
| IT1296550B1 (it) | Dispositivo per identificare quantificare e segnalare interruzioni della catena del freddo in prodotti surgelati o congelati. | |
| EA199900893A1 (ru) | Бактериальные плазмиды | |
| FI902803A7 (fi) | DNA-sekvenssi, joka koodaa a-amylaasi-pullulanaasientsyymiä | |
| ATE252111T1 (de) | O6-benzylguanin-enthaltende oligodesoxyribonukleotide und deren verwendung | |
| DE69809196D1 (de) | Mehrwertige kohlenhydrat-moleküle |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |